Empagliflozin in Patients with Chronic Kidney Disease
EMPA-KIDNEY Collaborative Group,
Herrington WG,
Staplin N,
Wanner C,
Green JB,
Hauske SJ,
Emberson JR,
Preiss D,
Judge P,
Mayne KJ,
Ng SYA,
Sammons E,
Zhu D,
Hill M,
Stevens W,
Wallendszus K,
Brenner S,
Cheung AK,
Liu ZH,
Li J,
Hooi LS,
Liu W,
Kadowaki T,
Nangaku M,
Levin A,
Cherney D,
Maggioni AP,
Pontremoli R,
Deo R,
Goto S,
Rossello X,
Tuttle KR,
Steubl D,
Petrini M,
Massey D,
Eilbracht J,
Brueckmann M,
Landray MJ,
Baigent C,
Haynes R
N Engl J Med. 2022; online ahead of print
EMPA-KIDNEY enrolled 6,609 patients with CKD who had eGFR ≥20 to <45 mL/min/1.73 m2 regardless of albuminuria levels or eGFR ≥45 to <90 mL/min/1.73 m2 and UACR ≥200 mg/g. In these patients, empagliflozin treatment led to a 28% lower risk of the primary endpoint of progression of kidney disease or CV death than placebo. Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. Empagliflozin also significantly reduced the rate of hospitalisation from any cause, but not death from any cause compared with placebo.